Background:Mean platelet volume (MPV) is an indicator of platelet activation and aggregation. MPV has been found to be related with the inflammation of certain disorders in recent studies.Aims:We sought to investigate whether MPV could be an indicator of inflammation in patients with Behçet disease (BD) and recurrent apthous stomatitis (RAS).Materials and Methods:Our study was designed as a retrospective case-control study and data was retrieved from our institutional database. We randomly generated a total of three study groups from our clinical archive. All controls were sex and age-matched and randomly selected by computer. Eighty-five patients with BD, 82 patients with RAS, and 721 healthy controls were included for the study design. We compared mean MPV values in the patient groups and controls.Results:We found no difference in the mean MPV value between BD group and BD-control group. The mean MPV value was significantly higher in patients with RAS than that in the RAS-control group (9.11 ± 1.01 fL vs. 8.76 ± 1.15 fL, P = 0.045). There was no difference in mean MPV level between BD and RAS group.Conclusion:The association between MPV and inflammatory skin diseases such as BD and RAS should be investigated prospectively in case-control studies.Limitations:Retrospective study design.
Pseudothrombocytopenia (PTCP) is characterized by a low platelet count (platelet count below 150 × 10 3 /μL) associated with in vitro platelet agglutination resulting from the presence of antiplatelet antibodies such as IgG, M, and A reacting with platelets in blood drawn into ethylenediaminetetraacetic acid (EDTA). The mechanism of this reaction appears to involve antiplatelet antibodies against glycoprotein IIb. Low platelet counts are detected in automated blood counts in EDTA tubes, whereas platelets form clusters in a peripheral blood smear. [1][2][3] The frequency of PTCP is reported in the rate of 0.09% to 0.21% in both healthy subjects and patients with various diseases. 3,4 Pseudothrombocytopenia incidence is 17% in patients with thrombocytopenia. 5 Although there is no evidence of purpura or bleeding in patients with PTCP, platelet function abnormalities have been rarely reported in a few studies based on the detection of the antibody. 1,6,7 To our best knowledge, there is no clinical study in which platelet aggregation with aggregometry is evaluated in PTCP. So we aimed to investigate platelet functions with aggregometry using adenosine diphosphate (ADP), collagen, epinephrine, and ristocetin. Materials and MethodsFifteen patients with PTCP (9 female with a mean age 48 ± 4 years) and 19 healthy persons (13 female with a mean age 55 ± 2 years) were enrolled in this study. Inclusion criteria of the patients with PTCP were low platelet count (<150 × 109/L) in routine EDTA-anticoagulated blood and the appearance of sufficient platelet clumping on peripheral smear. Average in 10 high power field on a blood film microscopically and multiplying by 15000 gives a platelet count reasonably close to automated machine counts in thousands per microliter. 8 Exclusion criteria were true thrombocytopenia such as autoimmune, liver, kidney disorders, hematological malignancies, solid tumors, and any disorder or drug affecting platelet functions in the last 15 days.Complete blood counts, peripheral smears, liver and kidney function tests, and platelet aggregation tests using ristocetin, epinephrine, collagen, and ADP were evaluated in patients and controls. The Gen S instrument (Beckman Coulter, Brea, CA) for whole blood counts and Chrono-Log 570 blood aggregation systems (Havertown, PA) for platelet aggregation were used. For platelet aggregation tests, 20 mL venous blood samples anticoagulated with 1 mL of 3.8% trisodium citrate were withdrawn. The time between blood sampling and the aggregation test was 30 minutes. Platelet aggregation varies directly with the interval between blood sampling and aggregation measurement over the first 30 minutes from sampling, then remains stable for the next 60 minutes of observation. Platelet-rich plasma (PRP) was prepared by centrifugation of the blood at 800 rpm for 15 minutes at 20°C. For each test, 450 μL PRP were collected in glass tubes and were fitted up in PRP washbowl. The supernatant was drawn into another tube, and the remaining PRP was centrifuged again at 4000 rpm for 10...
Amaç: Hipertansiyon artmış trombosit fonksiyonu ile ilişkilidir. Bazı antihipertansif ilaçların anti-trombosit aktiviteleri vardır. Biz bu çalışmada, losartanın adenozin difosfat (ADP), kollajen, epinefrin, ristosetin ile trombosit agregasyonuna, diğer hematolojik ve enflamatuvar parametreler üzerine etkilerinin araştırılmasını amaçladık. Objective: Hypertension is associated with increased platelet function. Some antihypertensive drugs have antiplatelet activity. In this study, we aimed to investigate the effects of losartan on platelet aggregation induced by adenosine diphosphate (ADP), collagen, epinephrine, ristocetin, other hematological and, inflammatory parameters. Materials and Methods: Twenty-five patients (19 female, 6 male; mean age: 54±8 years) with newly diagnosed hypertension were included in the study. All patients were with stage 1-2 essential hypertension according to the seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Initial blood pressure measurement was performed in all patients and losartan 100 mg/daily together with life style changes, such as diet and exercise was started. Platelet aggregation was evaluated with the use of ristocetin, epinephrine, collagen, and ADP. Complete blood count was also done. Platelet aggregation tests and blood pressure measurements were repeated after 8 weeks of therapy. Results: Systolic and diastolic blood pressure significantly decreased with losartan after 8 weeks (p<0.001). After treatment, there was no significant difference in platelet aggregation with ADP, collagen, and epinephrine (p>0.05). The aggregation with ristocetin significantly decreased (p=0.027). Besides, significantly lower hemoglobin and hematocrit levels were observed (p=0.034, p=0.039, respectively). Conclusion: Losartan may produce independent activities apart from its antihypertensive effects by providing significant reductions in platelet aggregation with ristocetin, and in hematocrit levels with hemoglobin. Therefore, it may be beneficial in the prevention of atherosclerosis and thrombosis.
Giriş Tip 2 diabetes mellitus (DM) tanılı hastalar yaşamları boyunca hastalığa ikincil gelişen komplikasyon ya da hastalık dışı nedenlerden dolayı cerrahi girişimle karşı karşıya kalabilmektedirler. Biz bu çalışmada, Tip 2 DM tanılı hastaların yaşamları boyunca geçirdikleri cerrahi müdahaleleri ve sıklıklarını belirlemeyi amaçladık. Materyal ve MetodTemmuz 2013-Aralık 2013 tarihleri arasında Tip 2 DM tanılı 922 hasta gözlemsel olarak çalışmaya alındı. Hastaların yaş, cinsiyet, ortalama hastalık süreleri, Tip 2 DM tanı öncesi ve sonrasında geçirilmiş operasyon öyküleri ile sayıları değerlendirilmeye alındı ve bilgiler olgu takip formuna kaydedildi.Bulgular Olguların %58.4'ü kadın olup yaş ortalaması 57.36 ±11.1 yıldı. Ortalama hastalık süresi 9.06±7.34 yıl idi. Hastaların %53.3'ü hayatları boyunca en az bir kez cerrahi operasyon geçirmiş olarak saptandı. Tip 2 DM tanısı konulmadan önce en az bir kez cerrahi müdahale geçirme sıklığı %33.7, tanı sonrasında ise %28.1 idi. Diyabet tanısı konulmadan önce en sık geçirilen operasyonların başında apendektomi (%7.1), kolesistektomi (%5.3) ve total abdominal histerektomi-bilateral salpingo ooferoktomi (%3.9) gelmekteydi. Diyabet tanısı konulduktan sonra ise en sık geçirilen operasyonlar sırasıyla kolesistektomi (%5), katarakt (%5), ortopedik cerrahi işlemler (%5) ve koroner arter by-pass cerrahisi (%4.1) idi.Sonuç Çalışmamızda Tip 2 DM tanılı hastaların %53.3'ünün yaşamlarının bir döneminde operasyon geçirdiğini saptadık. Diyabetli hastalarda cerrahi müdahale sıklığının yüksek olması preoperatif değerlendirmenin önemi artırmaktadır.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.